Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-1860.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary. J Am Coll Cardiol. 2019;74:1376-1414.
ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-1539.
Berger JS, Brown DL, Becker RC, et al. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121:43-49.
Cainzos-Achirica M, Miedema MD, McEvoy JW, et al. Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the MESA Study (Multi-Ethnic Study of Atherosclerosis). Circulation. 2020;141:1541-1553.
Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036-1046.
Greenland P, Blaha MJ, Budoff MJ, et al. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72:434-447.
Lloyd-Jones DM, Braun LT, Ndumele CE, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. Circulation. 2019;139:e1162-e1177.
McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379:1509-1518.
McNeil JJ, Woods RL, Nelson MR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med. 2018;379:1499-1508.
McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379:1519-1528.
Naghavi M, Maron DJ, Kloner RA, et al. Coronary artery calcium testing: a call for universal coverage. Prev Med Rep. 2019;15:100879.
Raber I, McCarthy CP, Vaduganathan M, et al. The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet. 2019;393:2155-2167.
Radiologyinfo. Cardiac CT for Calcium Scoring. Accessed October 1, 2020. https://www.radiologyinfo.org/en/info.cfm?pg=ct_calscoring
Roberts ET, Horne A, Martin SS, et al. Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA). PLoS One. 2015;10:e0116377.
Rumberger JA, Simons DB, Fitzpatrick LA, et al. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. Circulation. 1995;92:2157-2162.
United Kingdom National Health Service. Cardiovascular disease. Accessed October 1, 2020. https://www.nhs.uk/conditions/cardiovascular-disease/
Weber, L.A., Cheezum, M.K., Reese, J.M. et al. Cardiovascular Imaging for the primary prevention of atherosclerotic cardiovascular disease events. Curr Cardiovasc Imaging Rep. 2015;8:36.
Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA. 2019;321:277-287.

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Charles P. Vega, MD

Health Sciences Clinical Professor of Family Medicine
University of California
Irvine School of Medicine
Irvine, California

Disclosures

Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Glaxo Smith Kline

Michael Blaha, MD, MPH

Professor of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University
Baltimore, Maryland

Disclosures

Disclosure: Michael Blaha, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Akcea; Bayer; Novartis; Kowa; Novo Nordisk; Regeneron; Sanofi; 89Bio
Received grants for clinical research from: Aetna; Amgen

Editors

Lih-Fan Chang, MD, MPH

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lih-Fan Chang, MD, MPH, has disclosed no relevant financial relationships.

Gillian Griffith, BA (Mod), MA

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Gillian Griffith, BA (Mod), MA, has disclosed no relevant financial relationships.

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CME / ABIM MOC / CE

Patient Selection for Aspirin Therapy: Implications for Primary Care

Authors: Charles P. Vega, MD; Michael Blaha, MD, MPH
CME / ABIM MOC / CE Released: 10/26/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 10/26/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for primary care clinicians, cardiologists, diabetologists & endocrinologists, nurses and other clinicians who care for individuals with cardiovascular disease.

The goal of this activity is to guide clinicians on the role of aspirin in primary prevention of cardiovascular disease and how they can identify the patients who may benefit from it.

Upon completion of this activity, participants will:

Have greater competence related to
- Patient selection for aspirin therapy in the setting of primary prevention
- Appropriate use of aspirin therapy for cardioprevention in the setting of primary prevention

Disclosures

Faculty

Charles P. Vega, MD

Health Sciences Clinical Professor of Family Medicine
University of California
Irvine School of Medicine
Irvine, California

Disclosures

Disclosure: Charles P. Vega, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Glaxo Smith Kline

Michael Blaha, MD, MPH

Professor of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University
Baltimore, Maryland

Disclosures

Disclosure: Michael Blaha, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen; Akcea; Bayer; Novartis; Kowa; Novo Nordisk; Regeneron; Sanofi; 89Bio
Received grants for clinical research from: Aetna; Amgen

Editors

Lih-Fan Chang, MD, MPH

Medical Education Director, Medscape, LLC

Disclosures

Disclosure: Lih-Fan Chang, MD, MPH, has disclosed no relevant financial relationships.

Gillian Griffith, BA (Mod), MA

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Gillian Griffith, BA (Mod), MA, has disclosed no relevant financial relationships.

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Contact This Provider

For Nurses

Awarded 0.25 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education

CME / ABIM MOC / CE

Patient Selection for Aspirin Therapy: Implications for Primary Care

Authors: Charles P. Vega, MD; Michael Blaha, MD, MPHFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 10/26/2020

Valid for credit through: 10/26/2021, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to guide clinicians on the role of aspirin in primary prevention of cardiovascular disease and how they can identify the patients who may benefit from it.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC / CE Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Charles P. Vega, MD

Michael Blaha, MD, MPH

Editors

Lih-Fan Chang, MD, MPH

Gillian Griffith, BA (Mod), MA

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

CME / ABIM MOC / CE

Patient Selection for Aspirin Therapy: Implications for Primary Care

Target Audience and Goal Statement

Disclosures

Faculty

Charles P. Vega, MD

Michael Blaha, MD, MPH

Editors

Lih-Fan Chang, MD, MPH

Gillian Griffith, BA (Mod), MA

CME, CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

Patient Selection for Aspirin Therapy: Implications for Primary Care

Educational Impact Challenge